Why Arcutis Biotherapeutics, Inc.’s (ARQT) Stock Is Down 5.13%
As of Friday, November 06, Arcutis Biotherapeutics, Inc.’s ARQT share price has dipped by 5.13%, which has investors questioning if this is right time to buy.Rosalio Madrigal
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Rosalio Madrigal
Tudor Pop
Rosalio Madrigal
Cynthia McLaughlin
Jenna Brashear
| Share Statistics | ARQT | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $3,333.4 | $203.5 | 63% |
|
| Shares Out (Mil) | 136.8 | 55.2 | 68% |
|
| Institutional Ownership | 99.2% | 93.3% | 85% |
|
| Float (Mil) | 94.5 | 40.4 | 59% |
|
| Beta | 1.63 | 1.05 | 85% |
|
| Avg Daily Volume (000s) | 1,671 | 569 | 78% |
|
| Price Change (52-week) |
(5.5%) | 38.8% | 49% |
|
| Growth | ARQT | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | 34.7% | (10.7%) | 88% |
|
| EPS (5yr) | 49.3% | 15.4% | 93 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | (35.4%) | (15.7%) | 15% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 7 | 7 | 7 | |
| Current EPS | $0.197 | $0.327 | $1.094 | |
| Month Ago EPS | $0.232 | $0.425 | $1.338 | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 2 | 0 | 0 | |
| Three Months Ago EPS | $0.228 | $0.412 | $1.303 | |
| Year/Year Chg | 228.3% | (357.5%) | (1,583%) | |
| Financials | ARQT | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $509 | $40 | 41% |
|
| Net Income (TTM) (Mil) | $30 | ($44) | 50% |
|
| EPS (TTM) | $0.230 | ($1.400) | 47% |
|
| Operating Cash Flow (TTM) (Mil) | $60 | ($35) | 47% |
|
| Net Cash Flow (TTM) (Mil) | ($14) | $-0 | 30% |
|
| Long-Term Debt (Q1) (Mil) | $108 | $4 | 45% |
|
| Enterprise Value (Q1) (Mil) | $3,279 | $142 | 56% |
|
| Valuation | ARQT | Industry Median |
Percentile (All Stocks) |
|
| P/B | 13.59 | 1.96 | 95% |
|
| P/E | 121.5 | 16.9 | 96% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 2.5 | 0.9 | 77% |
|
| Ratios | ARQT | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 91.2% | 67.6% | 94% |
|
| Net Margin | 5.9% | (50.8%) | 50% |
|
| ROA | 6.7% | (47.0%) | 77% |
|
| ROE | 14.9% | (51.8%) | 70% |
|
| Liabilities to Assets | 53.5% | 29.6% | 47% |
|
| F-Score | 6 | 3 | 67% |
|
Arcutis Biotherapeutics, Inc. did not pass any screens on 11/20/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors